Home LiteratureArticle Details
PMID: 15766681 Published · ppublish English Journal Article Review

Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy.

Current opinion in immunology ·Vol. 17 ·No. 2 ·2005-04-00 ·Pages 195-201

Wrzesinski C, Restifo NP

Abstract

Adoptive T-cell immunotherapy combined with non-myeloablative lymphodepletion has emerged as the most effective immunotherapy treatment for patients with metastatic melanoma (objective response rates of 50%). The mechanisms underlying this major advance in the field of immunotherapy include the elimination of regulatory elements and increased access to activating cytokines. This results in the activation of low-affinity T cells, enabling them to destroy tumors. We propose that a more complete depletion of the patient's immune system followed by transplantation with hematopoietic stem cells, which can be genetically modified, would be more effective in the treatment of metastatic cancer.

MeSH Terms
Animals Cell Proliferation Hematopoietic Stem Cell Transplantation Humans Immunotherapy, Adoptive Lymphocyte Activation/immunology Lymphopenia/immunology,therapy Neoplasms/immunology,therapy Receptors, Antigen, T-Cell/immunology T-Lymphocytes/immunology
Chemicals
Receptors, Antigen, T-Cell
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Wrzesinski Claudia
National Cancer Institute, National Institutes of health, Clinical Research Center, Room 3-5816, 10 Center Drive, Bethesda, MD 20892-1201, USA. [email protected]
Restifo Nicholas P
References (60)
60 references, click to expand
  1. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance.
    J Clin Invest. 2004 Aug;114(4):551-9 PMID: 15314692
  2. Recombinant interleukin-7 induces proliferation of naive macaque CD4+ and CD8+ T cells in vivo.
    J Virol. 2004 Sep;78(18):9740-9 PMID: 15331707
  3. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
    Nat Med. 2004 Sep;10(9):942-9 PMID: 15322536
  4. Cancer immunotherapy: moving beyond current vaccines.
    Nat Med. 2004 Sep;10(9):909-15 PMID: 15340416
  5. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.
    J Exp Med. 2004 Sep 20;200(6):771-82 PMID: 15381730
  6. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis.
    J Exp Med. 2004 Oct 4;200(7):825-34 PMID: 15452177
  7. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.
    Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14639-45 PMID: 15381769
  8. CD24 expression on T cells is required for optimal T cell proliferation in lymphopenic host.
    J Exp Med. 2004 Oct 18;200(8):1083-9 PMID: 15477346
  9. Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases.
    J Immunol. 1994 Jun 15;152(12):5776-84 PMID: 8207207
  10. Naïve cytotoxic T lymphocytes spontaneously acquire effector function in lymphocytopenic recipients: A pitfall for T cell memory studies?
    Eur J Immunol. 1999 Feb;29(2):608-14 PMID: 10064077
  11. Survival of naive CD4 T cells: roles of restricting versus selecting MHC class II and cytokine milieu.
    J Immunol. 1999 Apr 1;162(7):3795-801 PMID: 10201896
  12. Designing and maintaining the mature TCR repertoire: the continuum of self-peptide:self-MHC complex recognition.
    Immunity. 1999 May;10(5):559-68 PMID: 10367901
  13. CD4+ T cell division in irradiated mice requires peptides distinct from those responsible for thymic selection.
    J Exp Med. 1999 Aug 2;190(3):367-74 PMID: 10430625
  14. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery.
    Immunity. 1999 Aug;11(2):173-81 PMID: 10485652
  15. Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts.
    Immunity. 1999 Aug;11(2):183-90 PMID: 10485653
  16. Forkhead-box transcription factors and their role in the immune system.
    Nat Rev Immunol. 2004 Nov;4(11):889-99 PMID: 15516968
  17. Modification of irradiation injury in mice and guinea pigs by bone marrow injections.
    J Natl Cancer Inst. 1951 Aug;12(1):197-201 PMID: 14874130
  18. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.
    J Immunol. 2004 Dec 15;173(12):7125-30 PMID: 15585832
  19. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.
    J Exp Med. 2005 Jan 3;201(1):139-48 PMID: 15630141
  20. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.
    Trends Immunol. 2005 Feb;26(2):111-7 PMID: 15668127
  21. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
    J Immunol. 2005 Mar 1;174(5):2591-601 PMID: 15728465
  22. Breaking tolerance in cancer immunotherapy: time to ACT.
    Curr Opin Immunol. 2005 Apr;17(2):187-94 PMID: 15766680
  23. Peripheral T cell expansion in lymphopenic mice results in a restricted T cell repertoire.
    Eur J Immunol. 2000 Dec;30(12):3380-6 PMID: 11093155
  24. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation.
    J Exp Med. 2000 Aug 21;192(4):557-64 PMID: 10952725
  25. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells.
    J Exp Med. 2000 Aug 21;192(4):549-56 PMID: 10952724
  26. Dependence of lymphopenia-induced T cell proliferation on the abundance of peptide/ MHC epitopes and strength of their interaction with T cell receptors.
    Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1728-33 PMID: 11172019
  27. IL-7 administration alters the CD4:CD8 ratio, increases T cell numbers, and increases T cell function in the absence of activation.
    J Immunol. 2001 Mar 1;166(5):3019-27 PMID: 11207251
  28. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients.
    J Immunol. 2001 Mar 1;166(5):3174-83 PMID: 11207270
  29. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo.
    Nat Immunol. 2000 Nov;1(5):426-32 PMID: 11062503
  30. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
    J Immunol. 1999 Nov 15;163(10):5211-8 PMID: 10553041
  31. Homeostatic expansion and phenotypic conversion of naïve T cells in response to self peptide/MHC ligands.
    Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13306-11 PMID: 10557316
  32. Control of homeostasis of CD8+ memory T cells by opposing cytokines.
    Science. 2000 Apr 28;288(5466):675-8 PMID: 10784451
  33. Cutting edge: naive T cells masquerading as memory cells.
    J Immunol. 2000 Aug 15;165(4):1733-7 PMID: 10925249
  34. Survival and homeostatic proliferation of naive peripheral CD4+ T cells in the absence of self peptide:MHC complexes.
    J Immunol. 2000 Sep 1;165(5):2458-64 PMID: 10946271
  35. CD4+ T cell survival is not directly linked to self-MHC-induced TCR signaling.
    Nat Immunol. 2000 Oct;1(4):329-35 PMID: 11017105
  36. T lymphocytes need IL-7 but not IL-4 or IL-6 to survive in vivo.
    Int Immunol. 2001 Jun;13(6):763-8 PMID: 11369703
  37. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Cancer Res. 2001 Jun 15;61(12):4766-72 PMID: 11406550
  38. IL-7 is critical for homeostatic proliferation and survival of naive T cells.
    Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8732-7 PMID: 11447288
  39. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
    J Exp Med. 2001 Sep 17;194(6):823-32 PMID: 11560997
  40. Homeostatic expansion occurs independently of costimulatory signals.
    J Immunol. 2001 Nov 15;167(10):5664-8 PMID: 11698438
  41. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.
    J Immunol. 2002 May 1;168(9):4272-6 PMID: 11970966
  42. Cytokine requirements for acute and Basal homeostatic proliferation of naive and memory CD8+ T cells.
    J Exp Med. 2002 Jun 17;195(12):1515-22 PMID: 12070279
  43. T cell homeostatic proliferation elicits effective antitumor autoimmunity.
    J Clin Invest. 2002 Jul;110(2):185-92 PMID: 12122110
  44. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
    J Immunol. 2002 Sep 1;169(5):2756-61 PMID: 12193750
  45. TCR and IL-7 receptor signals can operate independently or synergize to promote lymphopenia-induced expansion of naive T cells.
    J Immunol. 2002 Oct 1;169(7):3752-9 PMID: 12244169
  46. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
    Science. 2002 Oct 25;298(5594):850-4 PMID: 12242449
  47. Cutting edge: homeostatic proliferation of peripheral T lymphocytes is regulated by clonal competition.
    J Immunol. 2003 Jan 15;170(2):672-6 PMID: 12517927
  48. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens.
    Eur J Immunol. 2002 Nov;32(11):3267-75 PMID: 12555672
  49. Competition for self ligands restrains homeostatic proliferation of naive CD4 T cells.
    Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1185-90 PMID: 12525694
  50. Involvement of avidity for major histocompatibility complex in homeostasis of naive and memory T cells.
    J Exp Med. 2003 Apr 21;197(8):1007-16 PMID: 12707300
  51. Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells.
    Nat Med. 2003 Jul;9(7):952-8 PMID: 12778137
  52. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
    J Exp Med. 2003 Aug 18;198(4):569-80 PMID: 12925674
  53. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.
    J Immunol. 2003 Dec 1;171(11):5931-9 PMID: 14634104
  54. A role for TCR affinity in regulating naive T cell homeostasis.
    J Immunol. 2004 Jan 1;172(1):40-4 PMID: 14688307
  55. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy.
    Immunity. 2004 Jan;20(1):107-18 PMID: 14738769
  56. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
    Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1969-74 PMID: 14762166
  57. Spontaneous proliferation, a response of naive CD4 T cells determined by the diversity of the memory cell repertoire.
    Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3874-9 PMID: 15001705
  58. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.
    Annu Rev Immunol. 2004;22:531-62 PMID: 15032588
  59. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity.
    Cell. 2004 Apr 16;117(2):265-77 PMID: 15084263
  60. IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory.
    Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9357-62 PMID: 15197277
Article Info
Journal
Current opinion in immunology
Abbr.
Curr Opin Immunol
ISSN
0952-7915
DOI
10.1016/j.coi.2005.02.002
Email
[email protected]
Published
2005-04-00
Pages
195-201
Language
English
Region
England
NLM ID
8900118
PMCID
PMC2254579
Subset
IM
Grants
Intramural NIH HHS · Z01 BC010763-01 · United States
Intramural NIH HHS · Z99 CA999999 · United States
External Links
PubMed source DOI: 10.1016/j.coi.2005.02.002 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2